JPMorgan Slashes CEO’s Compensation and 3 Dow Movers to Track

McDonald’s Corporation (NYSE:MCD): Current price $91.84

The company has launched new packaging designs on all carry-out bags and fountain beverage cups with QR codes, saying that this initiative is its latest step in an ongoing commitment to supply consumers with information to help them make informed choices. Text, illustrations and a QR code will provide facts about the brand and make nutrition information easily accessible from mobile devices. The initiative starts this week in the United States and will continue being introduced globally through the year, with the text being translated into 18 different languages.

mcd

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

JPMorgan Chase & Co. (NYSE:JPM): Current price $46.40

The board of directors reduced Chief executive Jamie Dimon’s compensation for 2012 to $11.5 million as the company posted a 53-percent jump in fourth-quarter profit to $5.69 billion due to earnings on mortgages. A bank spokesperson said that, “Mr. Dimon bears ultimate responsibility for the failures that led to the losses in CIO and has accepted responsibility.”

jpm

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Microsoft Corporation (NASDAQ:MSFT): Current price $27.38

Microsoft is not pleased with the results of a recent test that found fault with its antivirus software. For a second consecutive time, its Security Essentials was unable to win certification from AV-Test, a German-based testing lab that evaluates the efficacy of antivirus products. However, out of 25 programs tested, only three failed to gain AV-Test’s  certification.

ms

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

Pfizer (NYSE:PFE): Current price $26.77

Pfizer’s partner GlycoMimetics has finished the enrollment of patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate. This randomized, double-blinded study evaluated the efficacy, safety and pharmacokinetics of GMI-1070 in hospitalized sickle cell disease patients experiencing vaso-occlusive crisis. GlycoMimetics has enrolled 76 patients from ages 12 to 65 at 22 trial sites in the United States and Canada. The company expects to report topline data in the second quarter.

pf

Don’t Miss: Here’s What Held Citigroup Back.